Brain natriuretic peptide as a cardiac hormone in essential hypertension

Kohno, Masakazu; Horio, Takeshi; Yokokawa, Koji; Murakawa, Koh‐ichi; Yasunari, Kenichi; Akioka, Kaname; Tahara, Akira; Toda, Iku; Takeuchi, Kazuhide; Kurihara, Naotsugu; Takeda, Tadanao

doi:10.1016/0002-9343(92)90011-y

Cited by 233 publications

(130 citation statements)

References 20 publications

Supporting

Mentioning

107

Contrasting

Unclassified

Order By: Relevance

“…In the above-mentioned study, BNP was not correlated with mean arterial pressure. Kohno et al 19 reported higher plasma ir-BNP levels in hypertensive patients with left ventricular hypertrophy (LVH) as established on echocardiography, when compared with those without LVH. In both of these reports, myocardial hypertrophy was found to be the main factor affecting BNP.…”

Section: Discussionmentioning

confidence: 99%

The association of brain natriuretic peptide and insulin resistance in obesity-related hypertension

Cikim

2007

J Hum Hypertens

View full text Add to dashboard Cite

Hypertension is frequently associated with obesity and natriuretic peptide levels are reported to decrease in obese subjects. Both the lower brain natriuretic peptide (BNP) concentration and insulin resistance are suggested to be associated with hypertension. However, their involvement in obesity-related hypertension has not been clearly defined. Forty-four obese women (21 normotensive and 23 hypertensive) and 25 healthy women matched for age were included in the study. Anthropometrical parameters were determined. Serum BNP, fasting insulin and glucose concentrations, and lipid parameters were evaluated. Insulin resistance was calculated using Homeostasis Model Assessment (HOMA) and Quantative Insulin Sensitivity Check Index (QUICKI) formulations. Within the obese groups, HOMA and QUICKI reflected the increased insulin resistance in hypertensive obese subjects with a significant correlation to blood pressure. The decrease in BNP in the obese groups was in favour of the hypertensive obese subjects (31.4376.43; 26.3674.29; and 17.5173.08 pg/ ml, respectively) with a fractional statistical significance between the hypertensive obese group and the controls (P ¼ 0.047). Only for the obese hypertensive group, fasting glucose, HOMA and QUICKI were significantly correlated with BNP. Moreover, fasting plasma glucose (R 2 ¼ 0.22, P ¼ 0.007) and fasting plasma insulin (R 2 ¼ 0.39, P ¼ 0.03) were independently correlated with BNP only for the obese hypertensive group. It can be concluded that the decrease in BNP concentrations in the obese hypertensive subjects seem to be well correlated with the insulin resistance.

show abstract

Section: Discussionmentioning

confidence: 99%

The association of brain natriuretic peptide and insulin resistance in obesity-related hypertension

Cikim

2007

J Hum Hypertens

View full text Add to dashboard Cite

show abstract

“…BNP will change (generally rise) in response to valvular heart disease, 6 hypertensive heart disease, 7 pericardial disease 8 or pulmonary heart disease; 9 indeed, BNP is reliably not elevated in non-cardiac disease. 10 Hence, its highly attractive and wellchampioned sensitivity sits beside the relative frailty of diagnostic non-specificity, at least for a variety of cardiac conditions or cardiac responses.…”

Section: Bnp Does Not Simply Mark Ventricular Systolic Dimensions or mentioning

confidence: 99%

Intraindividual temporal variance of biomarkers and the definition of individualized prognosis in cardiovascular patients

MacFadyen

2006

J Hum Hypertens

View full text Add to dashboard Cite

“…It has been revealed that BNP plays an important role in the regulation of body fluid and blood pressure in response to volume expansion and pressure overload [5,6]. Since BNP is a sensitive indicator of ventricular wall stress, the plasma level can easily increase in patients with cardiovascular diseases (CVD), including hypertension [5][6][7], congestive heart failure (CHF) [8], and acute myocardial infarction (AMI) [9].…”

mentioning

confidence: 99%

Characterization of Plasma Brain Natriuretic Peptide Level in Patients with Type 2 Diabetes

et al. 2005

View full text Add to dashboard Cite

Abstract. This study investigates whether the plasma brain natriuretic peptide (BNP) level is increased by the clinical traits of diabetes, including its complications, and whether these levels are affected by the presence of other combined diseases such as hypertension, hyperlipidemia, and coronary heart disease (CHD) in patients with diabetes. In 223 patients with Type 2 diabetes, the mean value of plasma BNP reached 32.3 ± 4.1 pg/mL. The levels significantly increased with age, hypertension, and CHD but not with the duration of diabetes, HbA1c level, or hyperlipidemia. With regard to the type of therapy, the BNP levels were significantly lower in the combinations of both sulfonylurea and metformin and sulfonylurea and pioglitazone than those in insulin alone. In addition, the BNP levels in the group with diabetic complications, including retinopathy and nephropathy, and macroalbuminuria were significantly elevated in comparison with those without these complications and macroalbuminuria. Interestingly, however, no difference was observed between these groups after removal of the values in patients with CHD. These results have clarified that the plasma BNP levels in diabetic patients could increase only by the progression of macrovascular diseases, such as CHD, but not by the current diabetic control or diabetic microvascular complications.

show abstract

Brain natriuretic peptide as a cardiac hormone in essential hypertension

Cited by 233 publications

References 20 publications

The association of brain natriuretic peptide and insulin resistance in obesity-related hypertension

The association of brain natriuretic peptide and insulin resistance in obesity-related hypertension

Intraindividual temporal variance of biomarkers and the definition of individualized prognosis in cardiovascular patients

Characterization of Plasma Brain Natriuretic Peptide Level in Patients with Type 2 Diabetes

Contact Info

Product

Resources

About